Physician profile
Anil K Agarwal
NPI 1639115413
$99,227.58
in general payments reported to CMS, 2019-2025
13 companies · $33K in 2025
The $33K reported for 2025 was more than what 98% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $20K · 2021: $18K · 2022: $6,100 · 2023: $38.58 · 2024: $10K · 2025: $33K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $43K · Food and Beverage: $200 · Education: $9.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $42,818.32 |
| Food and Beverage | $199.83 |
| Education | $9.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cormedix INC. | $38,657.65 | 2024-2025 | Defencath, Defencath |
| Astrazeneca Pharmaceuticals Lp | $21,934.75 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $12,801.00 | 2019-2020 | |
| Amgen INC. | $7,662.00 | 2020-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $5,625.05 | 2019-2021 | |
| Akebia Therapeutics INC | $5,435.00 | 2021-2024 | Auryxia, Vafseo |
| Rockwell Medical, INC. | $3,275.52 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $1,960.00 | 2019-2020 | |
| Pfizer INC. | $1,800.00 | 2025 | |
| Calliditas Therapeutics US INC. | $35.50 | 2023 | Tarpeyo |
| Vifor Pharma, INC. | $31.50 | 2019 | |
| Travere Therapeutics, INC. | $9.61 | 2023-2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anil Agarwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.